The Apoptosis Inhibitor Protein Survivin Is a Critical Cytoprotective Resistor against Silica-Based Nanotoxicity.

alveolar-capillary barrier amorphous silica nanoparticles cytotoxic response inflammation lung model nanotoxicity

Journal

Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216

Informations de publication

Date de publication:
12 Sep 2023
Historique:
received: 21 08 2023
revised: 08 09 2023
accepted: 09 09 2023
medline: 28 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Exposure to nanoparticles is inevitable as they become widely used in industry, cosmetics, and foods. However, knowledge of their (patho)physiological effects on biological entry routes of the human body and their underlying molecular mechanisms is still fragmented. Here, we examined the molecular effects of amorphous silica nanoparticles (aSiNPs) on cell lines mimicking the alveolar-capillary barrier of the lung. After state-of-the-art characterization of the used aSiNPs and the cell model, we performed cell viability-based assays and a protein analysis to determine the aSiNP-induced cell toxicity and underlying signaling mechanisms. We revealed that aSiNPs induce apoptosis in a dose-, time-, and size-dependent manner. aSiNP-induced toxicity involves the inhibition of pro-survival pathways, such as PI3K/AKT and ERK signaling, correlating with reduced expression of the anti-apoptotic protein Survivin on the protein and transcriptional levels. Furthermore, induced Survivin overexpression mediated resistance against aSiNP-toxicity. Thus, we present the first experimental evidence suggesting Survivin as a critical cytoprotective resistor against silica-based nanotoxicity, which may also play a role in responses to other NPs. Although Survivin's relevance as a biomarker for nanotoxicity needs to be demonstrated in vivo, our data give general impetus to investigate the pharmacological modulation of Survivin`s functions to attenuate the harmful effects of acute or chronic inhalative NP exposure.

Identifiants

pubmed: 37764575
pii: nano13182546
doi: 10.3390/nano13182546
pmc: PMC10535920
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : DO-1910/2-1

Références

Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
Beilstein J Nanotechnol. 2014 Aug 27;5:1380-92
pubmed: 25247121
Oncogene. 2014 Apr 3;33(14):1828-39
pubmed: 23624914
Dev Biol. 2002 Feb 15;242(2):75-87
pubmed: 11820807
Oncotarget. 2015 Sep 29;6(29):27187-98
pubmed: 26356670
Oxid Med Cell Longev. 2019 Jan 10;2019:8727925
pubmed: 30774747
Nat Nanotechnol. 2013 Oct;8(10):772-81
pubmed: 24056901
Gerontology. 2016;62(2):173-81
pubmed: 26159786
J Esthet Restor Dent. 2015 Sep-Oct;27(5):293-9
pubmed: 25439032
Nat Biotechnol. 2010 Dec;28(12):1300-3
pubmed: 21057497
Iran J Basic Med Sci. 2022 Jul;25(7):842-849
pubmed: 36033958
Int J Cancer. 2009 May 1;124(9):2033-41
pubmed: 19130609
J Appl Toxicol. 2014 Apr;34(4):424-35
pubmed: 24302550
Int J Cancer. 2005 Dec 10;117(5):755-63
pubmed: 15981204
Curr Med Chem. 2012;19(22):3748-62
pubmed: 22680924
EMBO Rep. 2006 Dec;7(12):1259-65
pubmed: 17099693
Cardiovasc Res. 2012 Apr 1;94(1):3-5
pubmed: 22379038
Mol Immunol. 2005 Feb;42(3):279-87
pubmed: 15589315
Bioengineered. 2020 Dec;11(1):130-140
pubmed: 31959045
Postepy Biochem. 2007;53(1):10-8
pubmed: 17718383
Ann N Y Acad Sci. 2022 Aug;1514(1):21-33
pubmed: 35580994
Parasitol Res. 2008 Jul;103(2):253-8
pubmed: 18438740
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
Hum Mutat. 2013 Feb;34(2):395-404
pubmed: 23161837
Biosci Rep. 2017 Nov 21;37(6):
pubmed: 29026006
J Am Chem Soc. 2012 Sep 26;134(38):15790-804
pubmed: 22924492
Respir Med. 2010 Oct;104(10):1391-5
pubmed: 20638828
Lancet. 2012 May 26;379(9830):2008-18
pubmed: 22534002
J Urol. 2011 Apr;185(4):1497-503
pubmed: 21334676
Mol Cell Biol. 2011 May;31(10):1949-58
pubmed: 21402781
Mol Cancer Ther. 2006 May;5(5):1087-98
pubmed: 16731740
Mol Carcinog. 2012 Jul;51(7):586-95
pubmed: 21761458
Biochem Biophys Res Commun. 2010 Apr 30;395(2):219-24
pubmed: 20361940
Cancer Lett. 2019 Sep 10;459:30-40
pubmed: 31128213
Korean Circ J. 2013 Jun;43(6):400-7
pubmed: 23882289
Nanotoxicology. 2011 Sep;5(3):393-405
pubmed: 20868236
Virchows Arch. 2010 Oct;457(4):497-507
pubmed: 20694477
J Transplant. 2018 Oct 1;2018:6492034
pubmed: 30364092
Hum Exp Toxicol. 2013 Feb;32(2):186-95
pubmed: 23315277
Cell Death Dis. 2010 Jul 01;1:e51
pubmed: 21364656
FASEB J. 2001 Jan;15(1):59-69
pubmed: 11149893
PLoS One. 2016 Mar 01;11(3):e0149684
pubmed: 26930065
Environ Sci Nano. 2016 Feb 1;3(1):56-66
pubmed: 26998307
Int J Nanomedicine. 2018 Apr 12;13:2279-2294
pubmed: 29695906
Oncogene. 2008 Jan 31;27(6):732-40
pubmed: 17653085
Nano Lett. 2008 Sep;8(9):3069-74
pubmed: 18698730
Beilstein J Nanotechnol. 2015 Feb 20;6:517-28
pubmed: 25821694
J Histochem Cytochem. 2006 Apr;54(4):385-95
pubmed: 16234507
Angew Chem Int Ed Engl. 2020 Mar 27;59(14):5567-5571
pubmed: 31916356
Arch Toxicol. 2010 Mar;84(3):183-90
pubmed: 19936708
Environ Toxicol Pharmacol. 2017 Dec;56:191-197
pubmed: 28957724
Expert Opin Biol Ther. 2021 Nov;21(11):1429-1441
pubmed: 33877952
Adv Drug Deliv Rev. 2010 Mar 8;62(3):362-74
pubmed: 19900497
Genes Dev. 2009 Jan 15;23(2):223-35
pubmed: 19171783
Nanotoxicology. 2013 May;7(3):235-50
pubmed: 22264124
Small. 2023 Aug;19(33):e2300871
pubmed: 37035950
Langmuir. 2010 Jan 5;26(1):328-35
pubmed: 19697952
Oncotarget. 2018 Jun 12;9(45):27835-27850
pubmed: 29963241
J R Soc Interface. 2010 Feb 6;7 Suppl 1:S41-54
pubmed: 19793744
J Cell Sci. 2019 Apr 4;132(7):
pubmed: 30948431
Int J Nanomedicine. 2012;7:3111-21
pubmed: 22904619
FASEB J. 2007 Jan;21(1):207-16
pubmed: 17099069
Small. 2009 Apr;5(7):846-53
pubmed: 19288475
J Am Soc Nephrol. 2013 Dec;24(12):2023-33
pubmed: 23949800
Adv Healthc Mater. 2018 Feb;7(4):
pubmed: 29193848
Clin Oral Investig. 2019 Jan;23(1):361-367
pubmed: 29671054
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5931-5937
pubmed: 32127478
Cancer Res. 2008 Jul 1;68(13):5159-66
pubmed: 18593915
Clin Epigenetics. 2019 Nov 12;11(1):157
pubmed: 31718698
Int J Mol Med. 2018 Oct;42(4):1771-1785
pubmed: 30015855
Mol Pharm. 2014 Mar 3;11(3):995-1006
pubmed: 24524365
Food Chem Toxicol. 2007 Oct;45(10):1856-67
pubmed: 17524541
Am J Physiol. 1998 Feb;274(2):L289-95
pubmed: 9486215
Toxicol In Vitro. 2017 Aug;42:308-318
pubmed: 28476499
Toxicology. 2012 Apr 11;294(2-3):61-79
pubmed: 22349641
Thorac Cardiovasc Surg. 2000 Oct;48(5):294-9
pubmed: 11100763
Adv Mater. 2017 Mar;29(9):
pubmed: 28084658

Auteurs

Christina Breder-Bonk (C)

Molecular and Cellular Oncology, University Medical Center Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany.

Dominic Docter (D)

Molecular and Cellular Oncology, University Medical Center Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany.

Matthias Barz (M)

Leiden Academic Center for Drug Research (LACDR), Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.

Sebastian Strieth (S)

Department of Otorhinolaryngology, University Medical Center Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Shirley K Knauer (SK)

Center for Medical Biotechnology (ZMB), Department of Molecular Biology II, University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany.

Désirée Gül (D)

Molecular and Cellular Oncology, University Medical Center Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany.

Roland H Stauber (RH)

Molecular and Cellular Oncology, University Medical Center Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany.

Classifications MeSH